Chronic Obstructive Pulmonary Disease (COPD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Chronic Obstructive Pulmonary Disease (COPD) Emerging Therapy and TPP Insights

Thelansis's "Chronic Obstructive Pulmonary Disease (COPD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chronic Obstructive Pulmonary Disease (COPD) Overview

Chronic Obstructive Pulmonary Disease (COPD) is a major global cause of chronic morbidity and mortality, currently ranking among the leading causes of death worldwide. The disease is characterized by persistent airflow limitation resulting from chronic inflammation, airway remodeling, and progressive destruction of lung parenchyma.

Pathophysiologically, COPD involves narrowing of small airways, loss of alveolar attachments, and reduced lung elasticity, which impair airflow, particularly during exhalation. This leads to air trapping, reduced gas exchange, and progressive respiratory dysfunction.

Diagnosis is confirmed using spirometry, with a post-bronchodilator FEV1/FVC ratio <0.70 indicating airflow obstruction. However, disease burden is not solely determined by airflow limitation; symptom severity (e.g., dyspnea, cough) and frequency of exacerbations play a critical role in clinical assessment.

Modern COPD management follows a multidimensional approach, combining spirometric classification with symptom burden and exacerbation risk to guide therapy. Treatment includes bronchodilators (LABA/LAMA), inhaled corticosteroids (ICS), and supportive care, aimed at reducing symptoms, preventing exacerbations, and improving quality of life.

Key Highlights

• COPD is a high-prevalence, chronic respiratory disease with significant global mortality burden
• US prevalent population expected to grow from ~28.1M to ~33.0M (~1.6% CAGR)

Market Overview

• Spain (mild-to-moderate segment) market projected to grow from ~$219M to ~$231M (~0.5% CAGR)
• Growth remains modest, driven by generic inhalation therapies and stable disease prevalence, with limited breakthrough innovation

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• SMSbiotech
• Haisco Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• Hoffmann-La Roche
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Genentech, Inc.
• Verona Pharma plc
• Keymed Biosciences Co.Ltd
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Reistone Biopharma Company Limited
• Sanofi
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Eurofarma Laboratorios S.A.
• AstraZeneca
• Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
• Regend Therapeutics
• Nuance Pharma (shanghai) Co., Ltd
• Upstream Bio Inc.
• Bambusa Therapeutics
• Areteia Therapeutics
• Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
• Anhui Hemay Pharmaceutical Co., Ltd
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Mabwell (Shanghai) Bioscience Co., Ltd.
• S-INFINITY Pharmaceuticals Co., Ltd
• Merck Sharp & Dohme LLC
• Mesoblast, Inc.
• Joincare Pharmaceutical Group Industry Co., Ltd
• Ganzhou Hemay Pharmaceutical Co., Ltd
• Chiesi Farmaceutici S.p.A.
• Bun Yao Biotechnology Co., Ltd
• Generate Biomedicines
• Rise Therapeutics LLC
• AeroRx Therapeutics Inc.